News | June 10, 2011

FDA Clears New Cordis Vascular Closure Device

June 10, 2011 – The U.S. Food and Drug Administration (FDA) granted market clearance for a new vascular closure device (VCD) that uses a bioabsorbable plug to seal femoral artery puncture sites. The Cordis Exoseal VCD is indicated for femoral artery puncture site closure, reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional catheterization.

The device is indicated for procedures using a standard 5, 6 or 7 French vascular sheath introducer with up to 12 cm working length. Additionally, it is indicated to reduce times to hemostasis and ambulation in patients who have undergone interventional catheterization procedures, using a standard 6 French vascular sheath introducer up to a 12 cm working length, who have received preprocedural and/or intraprocedural glycoprotein (GP) Ilb/Ia inhibitor therapy.

The bioabsorbable plug is made entirely of a synthetic, absorbable polymer (polyglycolic acid – PGA). PGA material has been used extensively by the medical community since 1970, primarily with bioabsorbable sutures. The PGA plug material is constructed to stop bleeding from the puncture site. The plug delivery system is designed to position and release the bioabsorbable plug to seal the puncture site in the main artery of the thigh (femoral artery).

The plug uses a standard introducer sheath. To help with the positioning and deployment, the delivery system incorporates two unique markers that provide the surgeon with visual targets to determine the location of the plug relative to the outside of the vascular wall prior to initiating and deploying the plug.

For more information: www.cordis.com

Related Content

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices | December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices | October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices | September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
Overlay Init